Sarasota, FL

Sarasota Arthritis Center

Arthritis

Spondylitis

Spondylarthritis

Axial Spondyloarthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Back Pain

Osteoporosis

Rheumatic Diseases

Overweight

Ixekizumab

Upadacitinib

ABT-494

Buprenorphine

Methotrexate

Tirzepatide

Zoledronic Acid

Lilly

AbbVie

Purdue Pharma

Novartis

condition

Obesity

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.

Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Sarasota Arthritis Center | Sarasota, FL

Site insights

Work at this site?

Active trials

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)

Trial sponsors